Further reading on observed adverse signal profiles from the investigational phase 2 programme is available in the Retatrutide Side Effects: Detailed Guide with Clinical Trial Insights 2026 article, which summarises published tolerability data for research planning purposes
Application of biomarkers for exposure and effect of polyhalogenated aromatic hydrocarbons in naturally exposed European otters ( Lutra lutra )
Liu B, Chen Y, St, Clair DK
Food and Drug Administration endorses the use of this injection for individuals aiming to lose weight, provided they align with specific health benchmarks: Possess a Body Mass Index (BMI) exceeding 27kg/m^2, coupled with one or more weight-associated health issues, such as hypertension, Type 2 diabetes, or elevated cholesterol levels
Individual results vary significantly based on starting body weight and metabolic factors